Forum - Olfac: anosmie et agueusie

Bienvenue sur le forum d'olfac.
Si une question vous turlupine, si vous voulez partager une expérience, si vous souhaitez nous confier une information n'hésitez pas, ce forum est là pour ça.

Accueil

Rechercher

Chat

Inscription

Connexion

Forum
--- Documentations, témoignages, reportages
------ Etude de l'effet du Dilatrane (Théophilline) sur l'Hyposmie

Vous devez vous connecter pour laisser un message.

Etude de l'effet du Dilatrane (Théophilline) sur l'Hyposmie
Drjoly	Posté le Vendredi 27 Novembre 2009 - 10:45
	Cher tous, Voici le résumé d'un article évaluant l'action de la theophilline sur l'odorat: NB: La theophylline est un médicament réservé au traitement symptomatique de l'asthme persistant et n'a pas d'indication dans la prise en charge des hyposmies en France. The American Journal of the Medical Sciences: June 2009 - Volume 337 - Issue 6 - pp 396-406 doi: 10.1097/MAJ.0b013e3181914a97 Clinical Investigation An Open-Label Controlled Trial of Theophylline for Treatment of Patients With Hyposmia Henkin, Robert I. MD, PhD; Velicu, Irina MS; Schmidt, Loren BS Background: To test the hypothesis that theophylline is effective in correcting smell loss in patients with hyposmia. Methods: Three hundred twelve patients with smell loss (hyposmia) were evaluated to determine characteristics of their loss by psychophysical measurements of detection and recognition thresholds, magnitude estimation and hedonic values for 4 odors (pyridine, nitrobenzene, thiophene, and amyl acetate) by use of a forced-choice 3-stimuli staircase design previously documented in a double-blind study. Patients were then treated in a fixed design open-label clinical trial with oral theophylline. Drug was given in equal divided doses from 200 to 800 mg daily for 2- to 8-month periods and subjective and psychophysical measurements of smell function and blood theophylline levels were measured; results were compared with those obtained before treatment. Results: Subjective smell loss improved in 157 (50.3%) patients; smell function was considered normal by 34 (21.7%). Overall, 10.9% of patients in the study considered smell function returned to normal. However, measurements of mean detection and recognition thresholds improved significantly at each drug level; measurements of mean magnitude estimation and hedonic also improved. Improvement was greater at drug doses of 600 and 800 mg than at 200 or 400 mg. Once improvement occurred, as long as treatment was maintained, it persisted for as long as follow-up was measured. Conclusion: Theophylline was effective in improving smell function in patients with smell loss. Improvement persisted as long as treatment was continued, which extended from 6 to 72 months. Critique personnelle: notez bien qu'il s'agit de patients hyposmiques et non anosmiques...grosse différence et que l'amélioration retrouvée n'est évaluée que sur 4 molécules et ne semble pas forçement persister après l'arret du traitement. Dr JOLY.B médecin ORL

Etude de l'effet du Dilatrane (Théophilline) sur l'Hyposmie

Drjoly

Posté le Vendredi 27 Novembre 2009 - 10:45

Cher tous,

Voici le résumé d'un article évaluant l'action de la theophilline sur l'odorat:
NB: La theophylline est un médicament réservé au traitement symptomatique de l'asthme persistant et n'a pas d'indication dans la prise en charge des hyposmies en France.

The American Journal of the Medical Sciences:

June 2009 - Volume 337 - Issue 6 - pp 396-406

doi: 10.1097/MAJ.0b013e3181914a97

Clinical Investigation

An Open-Label Controlled Trial of Theophylline for Treatment of Patients With Hyposmia
Henkin, Robert I. MD, PhD; Velicu, Irina MS; Schmidt, Loren BS

Background: To test the hypothesis that theophylline is effective in correcting smell loss in patients with hyposmia.
Methods: Three hundred twelve patients with smell loss (hyposmia) were evaluated to determine characteristics of their loss by psychophysical measurements of detection and recognition thresholds, magnitude estimation and hedonic values for 4 odors (pyridine, nitrobenzene, thiophene, and amyl acetate) by use of a forced-choice 3-stimuli staircase design previously documented in a double-blind study. Patients were then treated in a fixed design open-label clinical trial with oral theophylline. Drug was given in equal divided doses from 200 to 800 mg daily for 2- to 8-month periods and subjective and psychophysical measurements of smell function and blood theophylline levels were measured; results were compared with those obtained before treatment.
Results: Subjective smell loss improved in 157 (50.3%) patients; smell function was considered normal by 34 (21.7%). Overall, 10.9% of patients in the study considered smell function returned to normal. However, measurements of mean detection and recognition thresholds improved significantly at each drug level; measurements of mean magnitude estimation and hedonic also improved. Improvement was greater at drug doses of 600 and 800 mg than at 200 or 400 mg. Once improvement occurred, as long as treatment was maintained, it persisted for as long as follow-up was measured.
Conclusion: Theophylline was effective in improving smell function in patients with smell loss. Improvement persisted as long as treatment was continued, which extended from 6 to 72 months.

Critique personnelle: notez bien qu'il s'agit de patients hyposmiques et non anosmiques...grosse différence et que l'amélioration retrouvée n'est évaluée que sur 4 molécules et ne semble pas forçement persister après l'arret du traitement.

Dr JOLY.B

médecin ORL

Vous devez vous connecter pour laisser un message.

Ce sujet lu 2696 fois contient 0 réponse(s)

Retour à la liste des sujets du salon.